Introduction

Postoperative atrial fibrillation (POAF) is the most common complication in patients undergoing cardiac surgery [1]. The incidence of POAF reported in previous studies varies between 20% and 50%, depending on the definitions and methods of detection [2,3]. Despite the advances in surgical techniques and perioperative care, the incidence of POAF has increased continuously over the past decades, which is believed to be due to the aging of the population undergoing cardiac surgery [4]. POAF can cause significant morbidities, including hypotension, congestive heart failure, symptoms of palpitations and fatigue, and most seriously, embolic stroke [5]. Also, POAF has been shown to increase both the length of hospitalization (LOH) and total hospital costs [2,6]. Moreover, patients with POAF tend to have higher long-term mortality [7]. Therefore, the prevention of POAF is of great importance. Although many pharmacologic interventions have been used to prevent the development of POAF, such as β-blockers, sotalol and amiodarone, all of them have limited efficacy and are not free of side effects [4,8]. Thus, there is an urgent need to develop novel prophylactic strategies to prevent POAF and related morbidities.

Accumulating evidence from epidemiologic studies and clinical trials has indicated that fish consumption, as well as supplementation with fish oil is associated with a reduced risk of cardiovascular mortality [9,10,11]. Particularly, antiarrhythmia has been suggested to be an important mechanism underlying the beneficial effects of fish oil [12,13]. Experimental studies also suggest that fish oil, which mainly consists of two categories of marine omega-3 polyunsaturated fatty acids (n-3 PUFAs) – eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may exert direct or indirect antiarrhythmic action, especially in the setting of myocardial ischemia [12,13]. However, effects of fish oil supplementation on arrhythmia from atrium, such as POAF are still unclear. Although some experimental studies support that fish oil may prevent the development of atrial fibrillation (AF) associated with heart failure [14,15], and recent electrophysiologic studies in human also suggests that fish oil supplementation may reduce vulnerability to inducible AF [16,17], results of prospective randomized controlled trials evaluating the effect of fish oil supplementation on POAF are generally controversial [18,19,20,21,22,23,24,25]. Therefore, we performed a meta-

Abstract

Background: Influence of fish oil supplementation on postoperative atrial fibrillation (POAF) was inconsistent according to published clinical trials. The aim of the meta-analysis was to evaluate the effects of perioperative fish oil supplementation on the incidence of POAF after cardiac surgery.

Methods: Pubmed, Embase and the Cochrane Library databases were searched. Randomized controlled trials (RCTs) assessing perioperative fish oil supplementation for patients undergoing cardiac surgery were identified. Data concerning study design, patient characteristics, and outcomes were extracted. Risk ratio (RR) and weighted mean differences (WMD) were calculated using fixed or random effects models.

Results: Eight RCTs involving 2687 patients were included. Perioperative supplementation of fish oil did not significantly reduce the incidence of POAF (RR = 0.86, 95%CI 0.71 to 1.03, p = 0.11) or length of hospitalization after surgery (WMD = 0.10 days, 95% CI: 0.48 to 0.67 days, p = 0.75). Fish oil supplementation also did not affect the perioperative mortality, incidence of major bleeding or the length of stay in the intensive care unit. Meta-regression and subgroup analyses indicated mean DHA dose in the supplements may be a potential modifier for the effects of fish oil for POAF. For supplements with DHA >1 g/d, fish oil significantly reduced the incidence of POAF; while it did not for the supplements with a lower dose of DHA.

Conclusions: Current evidence did not support a preventative role of fish oil for POAF. However, relative amounts of DHA and EPA in fish oil may be important for the prevention of POAF.
analysis to systematically evaluate the effect of fish oil supplementation on POAF incidence after cardiac surgery.

Methods

The primary objective of this meta-analysis is to investigate the possible role of fish oil supplementation for the prevention of POAF. In addition, some other related outcomes, including the LOH and length of stay in the intensive care unit (ICU) after surgery, perioperative mortality, and incidence of major bleeding were also evaluated. We performed this systematic review and meta-analysis according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [26] and Cochrane Handbook guidelines [27].

Search strategy

Pubmed (from 1950 to November, 2012), Embase (from 1966 to November, 2012) and the Cochrane Library (Cochrane Center Register of Controlled Trials) were searched for relevant records, using the terms “omega-3 fatty acids”, “n-3 fatty acids”, “fish oil”, “fish-oil”, “marine oil”, “eicosapentaenoic acid”, “EPA”, “docosahexaenoic acid”, “DHA” paired with “atrial fibrillation”. The search was limited to studies in humans. We also analyzed reference lists of original and review articles using a manual approach. The final literature search was performed on November 25th, 2012.

Study selection

According to the objective of the current meta-analysis, studies were included for analysis if they met the following criteria: 1) published as full-length article or abstract in any language; 2) reported as a prospective, randomized, and controlled trial with a parallel design (regardless of sample size); 3) included adult human subjects (≥18 years of age) who underwent a cardiac surgery and assigned to perioperative fish oil supplementation (orally or intravenously).

Table 1. Baseline characteristics of the patients of included studies.

| Study           | Number of patients | Mean age (years) | Male (%) | BMI (kg/m²) | HTN (%) | DM (%) | Previous AF (%) | CRF (%) | COPD (%) | Previous Valve surgery (%) | Off-pump surgery (%) |
|-----------------|--------------------|------------------|----------|-------------|---------|--------|-----------------|---------|----------|---------------------------|---------------------|
| Calo 2005       | 160                | 65.5             | 85.0     | NR          | 32.5    | 0      | 9.4             | 16.3    | 55.8     | 39.7                      | 79.4                |
| Heidt 2009      | 102                | 66.4             | 68.6     | NR          | 32.0    | 0      | NR              | 14.6    | 84.3     | 40.3                      | 0                   |
| Saravanan 2010  | 103                | 67.0             | 79.4     | 27.8        | 32.0    | NR     | 9.4             | 16.3    | 55.8     | 39.7                      | 79.4                |
| Heidarsdottir 2010 | 168             | 67.0             | 79.4     | 27.8        | 32.0    | 0      | NR              | 14.6    | 84.3     | 40.3                      | 0                   |
| Farquharson 2011 | 194              | 64.0             | 72.2     | 30.5        | 63.1    | 15.1   | 16.3            | 32.0    | 84.3     | 40.3                      | 0                   |
| Sorice 2011a     | 93                | 65.5             | 84.9     | NR          | 66.7    | NR     | 9.4             | 16.3    | 55.8     | 39.7                      | 79.4                |
| Sorice 2011b     | 108                | 63.0             | 78.7     | NR          | 62.0    | 0      | NR              | 14.6    | 84.3     | 40.3                      | 0                   |
| Sandesara 2012  | 243                | 62.7             | 80.7     | NR          | 88.5    | 36.2   | NR              | 14.6    | 84.3     | 40.3                      | 0                   |
| Mozaffarian 2012 | 1516              | 63.7             | 72.2     | 28.3        | 75.6    | 26.0   | 7.8             | 11.3    | 56.7     | 42.2                      | 51.2                |

1The study by Sorice et al includes two randomized comparisons in patients who underwent off-pump or on-pump surgery. These two sets of data were analyzed separately in the meta-analysis. As Sorice 2011a and Sorice 2011b.

BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; CRF, chronic renal failure; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; NR, not reported.
intravenously) or a control group; 4) aimed to investigate the effect of fish oil supplementation on the prevention of POAF.

Data extraction and quality assessment
Two authors (WX and WW) independently performed the literature searching, data extraction, and quality assessment according to the inclusion criteria. Discrepancies were resolved by consensus. Extracted data include: 1) study design characteristics: randomization, allocation concealment, blinded and withdrawals/dropout; 2) patient characteristics: number, age, sex, major comorbidities, baseline parameters of echocardiogram and concurrent therapy; 3) surgery characteristics: coronary artery bypass graft (CABG) or valve surgery, off-pump or on-pump; 4) details of treatments: regimen of supplementation, dose of EPA and DHA, ratio of EPA to DHA, treatment in control group, and treatment and follow-up duration; 5) study outcomes: incidence of POAF, LOH and length of ICU stay after surgery, incidence of major bleeding and perioperative mortality.

The quality of the studies was first judged by Jadad Score, which evaluates the quality of randomization, generation of random numbers, concealment of treatment allocation, blinding, and reporting of withdrawals [28]. Trials scored one point for each area addressed, with a possible score between 0 and 5, where 5 represented the highest level of quality. Furthermore, we also used the 6 domains of the Cochrane risk of bias tool to evaluated the quality of the included studies, which include criteria concerning sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, select outcome reporting and other potential threats to validity [27].

Statistical analysis
Dichotomous data were analyzed using risk ratio (RR) with 95% confidence intervals (CI), whereas continuous variables were analyzed using weighted mean differences (WMD). Inter-study heterogeneity was formally tested using Cochrane's Q test, and significant heterogeneity was considered existing if p value was <0.10. The I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance [29], was also examined, and a value of I²>50% indicated significant heterogeneity among the trials [30]. Pooled analyses were calculated using fixed-effect models if no significant heterogeneity was detected by Cochrane’s Q test, whereas random-effect models were applied in case of significant heterogeneity across studies. If significant heterogeneity was detected among the included studies, meta-regression studies and predefined subgroup analyses were performed to explore the possible influence of patients and study characteristics (including the numbers of the patients, mean age, gender, comorbidities, concurrent mediations, surgery types, total dose of fish oil, dose of EPA and DHA, POAF incidence in controls, and Jadad Scores) on the outcomes. Median values of continuous variables were used as cut-off values for grouping studies, and random-effect models were applied for the subgroup analyses. Besides, potential publication bias was assessed with Egger regression asymmetry test [31] and funnel plots; p values were two-tailed and statistical significance was set at 0.05. Meta-analysis and statistical analysis was performed with RevMan software (Version 5.1; Cochrane Collaboration, Oxford, UK) and Stata software (Version 12.0; Stata Corporation, College Station, TX).

Results
Search results
A total of 359 records were identified through the database searching, and 339 were excluded because they did not describe randomization or controlling, or because the objectives of these studies were irrelevant to the present meta-analysis, or because they were reviews, editorials or duplications. Of the 20 potentially relevant records screened, eight [18,19,20,21,22,23,24,25] met the selection criteria for the current meta-analysis (Figure 1). Twelve records were further excluded because six records were not randomized controlled trials; three were duplicate publications; two were trial-design papers; and one did not report available data of the related outcomes.

Study characteristics
Overall, eight studies [18,19,20,21,22,23,24,25] with 2687 patients (1337 in the fish oil group and 1350 in the control group) were included in the meta-analysis. Because the study by Sorice et al [23] includes two randomized comparisons in patients who underwent off-pump or on-pump surgery, our meta-analysis finally consists of nine sets of data comparing fish oil supplementation with controls for the prevention of POAF. The characteristics of the included studies are presented in Table 1 and 2. All the studies included patients of 18 years or older, who were scheduled for cardiac surgery in the following days and of sinus rhythm on screening. Six of the studies excluded patients with previous diagnosed AF [18,19,20,21,22,23], while the other two did not [24,25]. The number of the included patients in each
| Study         | Design       | EPA+DHA | EPA | DHA | EPA/DHA Control | Treatment duration | Follow-up duration | Definition of POAF | POAF detection methods | POAF incidence in controls | Jadad Score |
|--------------|--------------|---------|-----|-----|----------------|-------------------|-------------------|------------------|------------------------|---------------------------|------------|
| Calo 2005    | R, OL        | Oral: 1.74 | 0.58 | 1.16 | 0.5           | No treatment      | At least 5 days before surgery until discharge | ECG confirmed AF (>5 min) or AF requiring intervention | Continuous monitoring at least 4 days after surgery; daily ECG | 33.3 3 |
| Heidt 2009   | R, DB, PC    | IV: 3.49 | 1.65 | 1.84 | 0.9           | Free fatty acids  | At least 0.5 day before surgery until leave ICU | ECG confirmed AF (>15 min) | Continuous monitoring and daily ECG | 30.0 3 |
| Saravanan 2010 | R, DB, PC    | Oral: 1.72 | 0.94 | 0.78 | 1.2           | Olive oil         | 17 days (median) before surgery until discharge | ECG confirmed AF (>0.5 min) | Continuous monitoring at least 5 days after surgery; daily ECG | 43.1 4 |
| Heidarsdottir 2010 | R, DB, PC   | Oral: 2.24 | 1.24 | 1.00 | 1.2           | Olive oil         | 6 days (median) before surgery until discharge or 14 days after surgery | ECG confirmed AF (>5 min) | Continuous monitoring until discharge | 54.1 3 |
| Farquharson 2011 | R, DB, PC    | Oral: 4.60 | 2.70 | 1.90 | 1.4           | Sunola            | 21 days before surgery until discharge or 6 days after surgery | ECG confirmed AF (>10 min) or AF requiring intervention | Continuous monitoring at least 3 days after surgery; daily ECG | 48.5 5 |
| Sorice 2011a | R, OL        | Oral: 1.74 | 0.58 | 1.16 | 0.5           | No treatment      | 5 days before surgery until discharge | ECG confirmed AF (>5 min) or AF requiring intervention | Continuous monitoring at least 4 days after surgery; daily ECG | 12.5 2 |
| Sorice 2011b | R, OL        | Oral: 1.74 | 0.58 | 1.16 | 0.5           | No treatment      | 5 days before surgery until discharge | ECG confirmed AF (>5 min) or AF requiring intervention | Continuous monitoring at least 4 days after surgery; daily ECG | 31.6 2 |
| Sandesara 2012 | R, DB, PC    | Oral: 3.36(preop), 1.68(postop) | 1.07 | 0.86 | 1.24          | Corn oil          | 2.5 days (median) before surgery until 14 days after surgery | ECG confirmed AF requiring intervention | Continuous monitoring and daily ECG | 32.5 3 |
| Mozaffarian 2012 | R, DB, PC    | Oral: 8.40/3—5d or 6.72/6d (preop), 1.68(postop) | 1.03 | 0.83 | 1.24          | Olive oil         | 2-5 days before surgery until discharge or 10 days after surgery | ECG confirmed AF (>0.5 min) | Continuous monitoring at least 5 days after surgery; daily ECG | 30.7 5 |

1The study by Sorice et al includes two randomized comparisons in patients who underwent off-pump or on-pump surgery. These two sets of data were analyzed separately in the meta-analysis, as Sorice 2011a and Sorice 2011b. EPA, eicosapentaenoic acid; DHA, ducosahexaenoic acid; AF, atrial fibrillation; R, randomized; OL, open-label; DB, double-blind; PC, placebo-controlled; IV, intravenous; ICU, intensive care unit; ECG, electrocardiogram. doi:10.1371/journal.pone.0072913.t002
comparison varied from 93 to 1516, with the mean age ranging from 62.7 to 67.0 years. The concurrent medications included β-blockers, angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), and statins in all of the studies, while one study also permitted amiodarone [25]. All of the studies enrolled patients who were scheduled for CABG, of which four studies [21,22,24,25] also included patients who were admitted for valve surgery. Fish oil was supplied orally in seven studies [18,20,21,22,23,24,25], while the other one study [19] applied an intravenous regimen. For the two studies [24,25] using a loading dose before surgery, we calculated the mean dose of fish oil supplied for each day according to the total amounts of supplementation and days of treatment. Overall, the mean dose of fish oil varied from 1.72 to 4.60 g/d, with the ratio of EPA to DHA varied from 0.5 to 1.4. The follow-up duration varied from during ICU stay or hospitalization to 14 days after surgery. Of note, the definition and detection of POAF varied among the individual trials as shown in Table 2. None of these studies reported serious adverse events which were deemed to be caused by fish oil supplementation.

Data quality
The Jadad Scores of the eight studies ranged from 2 to 5. All of the included comparisons were randomized and controlled trials, with six [8–11,13,14] in a double-blind design and two [18,23] of an open-label design. Four [18,20,22,25] of the studies reported the methods of random sequence generation, and only two [22,25] reported allocation concealment. Details of withdrawals and dropout were reported in all studies. The details of risks of biases of the included studies according to the Cochrane assessment tool are listed in Table 3 and Figure 2. Two of the trials [22,25] were at low risk of bias for all quality criteria.

Effect of fish oil on incidence of postoperative atrial fibrillation
All of the nine included comparisons investigated the effect of fish oil on the incidence of POAF, and the heterogeneity among them was significant (I² = 50%, p = 0.04). The pooled result with a random-effect model indicated that fish oil supplementation was not associated with a significant reduction of POAF (RR = 0.86, 95% CI 0.71 to 1.03, p = 0.11; Figure 3A). The result was not significantly different when we excluded the study in which fish oil

![Figure 3. Forest plots from meta-analyses for the effects of fish oil supplementation on incidence of POAF (A) and LOH after cardiac surgery (B). The effect size of each study is proportional to the statistical weight. The diamond indicates the overall summary estimate for the analysis; the width of the diamond represents the 95% CI. POAF, postoperative atrial fibrillation; LOH, length of hospitalization; IV, inverse variance; CI, confidence interval; DHA, docosahexaenoic acid; SD, standard deviation. doi:10.1371/journal.pone.0072913.g003](image-url)
was supplied intravenously (RR = 0.88, 95% CI 0.72 to 1.06, p = 0.18).

In view of the considerable heterogeneity, we performed meta-regression analyses to explore the potential relationship between predefined study characteristics and the effect of fish oil supplementation on POAF. Results of the meta-regression tests suggested that mean dose of DHA was positively related to the preventative effect of fish oil for POAF (coefficient = 0.29, p = 0.03; Table 4 and Figure 4A), which could largely explain the heterogeneity. Other study characteristics, including the numbers of the patients, mean age, gender, comorbidities, concurrent medications, surgery types, total dose of fish oil, dose of EPA, POAF incidence in controls, and Jadad Scores seemed not to influence the possible effect of fish oil on POAF.

Subsequent subgroup analyses also revealed that fish oil supplementation significantly reduced the incidence of POAF in patients taking DHA ≥ 1.0 g/d [18, 19, 22, 25] (RR = 0.63, 95% CI 0.48 to 0.83, p < 0.001; Figure 3A and Table 5), while did not in those taking DHA < 1.0 g/d [20, 21, 24, 25] (RR = 1.00, 95% CI 0.89 to 1.13, p = 0.99; Figure 3A and Table 5), which is consistent with the meta-regression results. Furthermore, we also found that fish oil reduced the risk of POAF more significantly among patients who were supplied with fish oil of ratio of EPA to DHA ≥ 0.29 (RR = 0.63, 95% CI 0.48 to 0.83, p < 0.001; Figure 3A and Table 5), which is consistent with the meta-regression results.

In Cochrane risk of bias assessment, the studies were rated as follows:

| Study         | Sequence generation | Allocation concealment | Blinding of participants | Allocation concealment | Blinding of outcome assessment | Incomplete outcome data | Selective outcome reporting | Other potential threats |
|---------------|---------------------|------------------------|--------------------------|------------------------|-------------------------------|-------------------------|--------------------------|--------------------------|
| Cabo 2005     | YES                 | UNCLEAR                | YES                      | YES                    | YES                           | NO                      | NO                       | YES                      |
| Heidt 2009    | UNCLEAR             | UNCLEAR                | YES                      | UNCLEAR                | YES                           | NO                      | NO                       | UNCLEAR                 |
| Saravanan 2010| UNCLEAR             | YES                    | UNCLEAR                  | UNCLEAR                | UNCLEAR                       | YES                     | YES                      | UNCLEAR                 |
| Faghihian 2010| UNCLEAR             | UNCLEAR                | YES                      | UNCLEAR                | UNCLEAR                       | NO                      | NO                       | UNCLEAR                 |
| Calvani 2011  | YES                 | UNCLEAR                | YES                      | YES                    | YES                           | NO                      | NO                       | YES                      |
| Sorice 2011a1 | UNCLEAR             | UNCLEAR                | NO                       | NO                     | NO                            | YES                     | UNCLEAR                 |
| Sorice 2011b1 | UNCLEAR             | UNCLEAR                | NO                       | NO                     | NO                            | YES                     | UNCLEAR                 |
| Sandesara 2012| UNCLEAR             | UNCLEAR                | YES                      | YES                    | YES                           | YES                     | YES                      | YES                      |
| Mozaffarian 2012| UNCLEAR         | YES                    | YES                      | YES                    | YES                           | YES                     | YES                      | YES                      |

The study by Sorice et al includes two randomized comparisons in patients who underwent off-pump or on pump surgery. These two sets of data were analyzed separately in the meta-analysis at Sorice 2011a and Sorice 2011b.

**Table 3.** Cochrane risk of bias assessment.

**Figure 4.** Meta-regression analyses between mean DHA dose and effects of fish oil on POAF incidence (A) and LOH after cardiac surgery (B). POAF, postoperative atrial fibrillation; LOH, length of hospitalization; DHA, ducosahexaenoic acid; RR, risk ratio; WMD, weighed mean difference.

doi:10.1371/journal.pone.0072913.g004

In view of the considerable heterogeneity, we performed meta-regression analyses to explore the potential relationship between predefined study characteristics and the effect of fish oil supplementation on POAF. Results of the meta-regression tests suggested that mean dose of DHA was positively related to the preventative effect of fish oil for POAF (coefficient = 0.29, p = 0.03; Table 4 and Figure 4A), which could largely explain the heterogeneity. Other study characteristics, including the numbers of the patients, mean age, gender, comorbidities, concurrent medications, surgery types, total dose of fish oil, dose of EPA, POAF incidence in controls, and Jadad Scores seemed not to influence the possible effect of fish oil on POAF.

Subsequent subgroup analyses also revealed that fish oil supplementation significantly reduced the incidence of POAF in patients taking DHA ≥ 1.0 g/d [18, 19, 22, 25] (RR = 0.63, 95% CI 0.48 to 0.83, p < 0.001; Figure 3A and Table 5), while did not in those taking DHA < 1.0 g/d [20, 21, 24, 25] (RR = 1.00, 95% CI 0.89 to 1.13, p = 0.99; Figure 3A and Table 5), which is consistent with the meta-regression results. Furthermore, we also found that fish oil reduced the risk of POAF more significantly among patients who were supplied with fish oil of ratio of EPA to
Table 4. Association of study characteristics and the pooled outcomes: univariate meta-regression analysis.

| RR of POAF incidence | WMD of LOH after surgery |
|----------------------|--------------------------|
|                       | Coefficient | 95% CI | p   | Coefficient | 95% CI | p   |
| Number of patients    | 0.00007     | −0.00026 to 0.00039 | 0.65 | −0.00006 | −0.00163 to 0.00151 | 0.93 |
| Mean age (years)      | 0.03        | −0.09 to 0.15      | 0.58 | −0.09     | −0.66 to 0.48      | 0.73 |
| Male (%)              | 0.0009      | −0.0414 to 0.0431  | 0.96 | −0.009    | −0.188 to 0.170    | 0.91 |
| HTN (%)               | −0.007      | −0.028 to 0.013    | 0.44 | −0.018    | −0.070 to 0.034    | 0.43 |
| DM (%)                | −0.02       | −0.06 to 0.02      | 0.48 | −0.03     | −0.11 to 0.06      | 0.51 |
| CRF (%)               | −0.008      | −0.178 to 0.162    | 0.90 | −0.03     | −0.09 to 0.03      | 0.36 |
| COPD (%)              | −0.03       | −0.07 to 0.01      | 0.19 | −0.02     | −0.13 to 0.08      | 0.57 |
| Mean LVEF (%)         | −0.003      | −0.053 to 0.046    | 0.86 | −0.12     | −0.36 to 0.12      | 0.25 |
| Mean LAD (mm)         | 0.07        | −0.24 to 0.38      | 0.68 | −0.12     | −1.11 to 0.87      | 0.72 |
| On β-blockers (%)     | 0.007       | −0.004 to 0.018    | 0.17 | 0.06      | −0.12 to 0.24      | 0.36 |
| On ACEI/ARB (%)       | 0.004       | −0.018 to 0.025    | 0.69 | −0.003    | −0.075 to 0.070    | 0.93 |
| On statins (%)        | 0.01        | −0.01 to 0.03      | 0.26 | 0.05      | −0.02 to 0.12      | 0.19 |
| Valvular surgery (%)  | 0.001       | −0.008 to 0.011    | 0.74 | 0.005     | −0.048 to 0.038    | 0.78 |
| Off-pump surgery (%)  | −0.0004     | −0.0155 to 0.0148  | 0.96 | −0.0005   | −0.0272 to 0.0261  | 0.96 |
| Fish oil dose (g/d)   | −0.08       | −0.24 to 0.08      | 0.27 | 0.08      | −0.91 to 1.08      | 0.85 |
| EPA dose (g/d)        | −0.09       | −0.36 to 0.19      | 0.48 | −0.24     | −1.98 to 1.49      | 0.74 |
| DHA dose (g/d)        | −0.29       | −0.50 to −0.08     | 0.03 | 2.1       | −4.0 to −0.2       | 0.04 |
| EPA/DHA               | 0.48        | −0.09 to 1.05      | 0.08 | 1.17      | −0.25 to 2.59      | 0.12 |
| POAF incidence in controls (%) | 0.005 | −0.014 to 0.024 | 0.58 | 0.006 | −0.070 to 0.081 | 0.86 |
| Jadad Score           | 0.05        | −0.13 to 0.24      | 0.52 | 0.01      | −0.75 to 0.77      | 0.97 |

RR, relative risk; POAF, post-operative atrial fibrillation; WMD, weighed mean difference; LOH, length of hospitalization; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus; CRF, chronic renal failure; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

doi:10.1371/journal.pone.0072913.t004

DHA <1.2 [18,19,23] than those supplied with fish oil of a higher ratio [20,21,22,24,25] (p = 0.001; Table 5), which further suggested that the relative amounts of DHA and EPA in fish oil supplements may influence its possible effect for POAF prevention. Besides, subgroup analyses also suggested that study design may potentially impact the effect of fish oil on POAF. Specifically, fish oil supplementation reduced the risk of POAF only in studies of an open-label design [19,23], but did not in studies with a double-blind design [19,20,21,22,24,25]. Of note, these open-label studies were all with a higher dose of DHA (>1.0 g/d).

Effects of fish oil on the length of hospitalization after surgery

Eight comparisons [18,20,21,22,23,24,25], of which fish oil was all supplied orally, including 1285 patients in the fish oil groups and 1300 patients in the control groups, investigated the influence of fish oil supplementation on LOH after cardiac surgery. Overall, the pooled analysis indicated that fish oil did not have a significant influence on LOH (WMD = 0.10 days, 95% CI = −0.48 to 0.67 days, p = 0.73; Figure 3B), although significant heterogeneity was found (I² = 69%, p = 0.002). Results of meta-regression analyses suggested that mean dose of DHA was positively related to the reduction of LOH after fish oil supplementation (coefficient = −2.1, p = 0.04; Table 4 and Figure 4B). Similarly, results of subgroup analyses also suggested that fish oil may significantly reduce LOH after surgery in patients taking DHA >1g/d [18,22,23] (WMD = −0.65 days, 95% CI = −1.21 to −0.08 days, p = 0.02; Figure 3B and Table 5), but did not in patients taking a lower dose of DHA [20,21,24,25]. Consistently, lower ratio of EPA to DHA (<1.2) was also associated with a significant reduction of LOH after surgery [18,23] (Table 5). Of note, the two studies with a lower ratio of EPA to DHA were all of an open-label design. Besides, the results of subgroup analyses suggested that preoperative use of β-blockers may influence the effect of fish oil on LOH. It seemed that fish oil may increase LOH in studies which included more patients taking β-blockers (>70%, Table 5), although meta-regression results did not support baseline β-blockers usage as a significant modifier of the effects of fish oil on LOH after surgery (Table 4).
incidence of POAF (Egger’s test p = 0.18) or LOH after surgery (Egger’s test p = 0.79). For the other endpoints of the current analyses, we were unable to estimate the publication biases due to limited number of studies included.

Discussion

In this study, by pooling the results of available randomized controlled trials, we did not find that perioperative fish oil supplementation could significantly reduce the incidence of POAF or LOH after cardiac surgery. However, significant heterogeneity existed among these studies. Of note, results of meta-regression and subgroup analyses suggested that relative amount of DHA and EPA seemed to be a potential modifier to the effects of fish oil on POAF and LOH. Specifically, fish oil may reduce the POAF incidence and LOH in studies with supplements of mean DHA dose over 1.0 g/d or ratio of EPA to DHA, but did not in studies with supplements of a lower dose of DHA or a higher ratio of EPA to DHA. In addition, current evidence also did not support fish oil supplementation could significantly affect perioperative mortality, incidence of major bleeding, or the length of ICU stay after cardiac surgery.

Early prospective cohort study indicated that fish consumption with high n-3 PUFAs is associated with a lower incidence of AF in humans after follow-up for 12 years [32], suggesting that fish oil supplementation may be applied as a strategy for the long-term primary prevention of AF. However, some similar dietary studies [33,34,35,36] published later failed to show an association between increased fish or n-3 PUFAs consumption and decreased risk of incident AF. On the other hand, many small-scaled controlled trials and meta-analyses observed that supplementation with fish oil could favorably affect some pathophysiological processes which contribute to the pathogenesis of AF, including inflammation [37,38], endothelial dysfunction [39], ventricular remodeling [40], and possibly autonomic disturbance [41,42]. These findings promoted related studies in humans to investigate whether supplementation with fish oil can prevent the incidence of POAF. Although the results of some early studies [18,19] and meta-analysis [43] seemed to be promising, a recent published large-scale trial [25] including 1516 such patients failed to support the potential preventative role of perioperative fish oil supplementation for the incidence of POAF. Results of our meta-analysis, by including these published randomized controlled trials, also did not show a significant association between fish oil supplementation and reduced POAF incidence, though considerable heterogeneity was detected among the studies. Therefore, currently there is no sufficient evidence to recommend fish oil as a preventative measure for POAF.

Interestingly, we found that relative amount of DHA and EPA in the supplements seemed to be a significant modifier to the effect...
Table 5. Subgroup analyses for the association of prespecified study characteristics and overall outcomes.

| Study design | POAF incidence | LOH after surgery |
|--------------|----------------|------------------|
|              | RR [95% CI]    | WMD [95% CI]     |
|              | p^1            | p^2              |
|              | p^1            | p^2              |

**Double-blind studies**
- Studies (patients), n: 6 (2326)
- I^2: 16%
- RR: 0.95 [0.83, 1.09]
- p^1: 0.47
- Studies (patients), n: 5 (2224)
- I^2: 73%
- WMD: 0.44 [0.31, 1.20]
- p^2: 0.25

**Non double-blind studies**
- Studies (patients), n: 3 (361)
- I^2: 0%
- RR: 0.48 [0.31, 0.75]
- p^1: 0.001
- Studies (patients), n: 3 (361)
- I^2: 0%
- WMD: 0.61 [1.19, 0.03]
- p^2: 0.04

**Number of patients**
- Studies (patients), n: 5 (566)
- I^2: 69%
- RR: 0.66 [0.38, 1.15]
- p^1: 0.14
- Studies (patients), n: 4 (464)
- I^2: 65%
- WMD: 0.31 [0.31, 1.20]
- p^2: 0.25

**Mean age**
- Studies (patients), n: 4 (1960)
- I^2: 38%
- RR: 0.87 [0.66, 1.15]
- p^1: 0.33
- Studies (patients), n: 4 (1960)
- I^2: 72%
- WMD: 0.44 [0.38, 1.05]
- p^2: 0.25

**Male**
- Studies (patients), n: 5 (2088)
- I^2: 50%
- RR: 0.84 [0.68, 1.05]
- p^1: 0.13
- Studies (patients), n: 4 (1986)
- I^2: 0%
- WMD: 0.02 [0.28, 0.24]
- p^2: 0.89

**HTN**
- Studies (patients), n: 4 (1981)
- I^2: 70%
- RR: 0.87 [0.65, 1.13]
- p^1: 0.52
- Studies (patients), n: 4 (1998)
- I^2: 56%
- WMD: 0.32 [0.80, 1.15]
- p^2: 0.57

**DM**
- Studies (patients), n: 4 (1813)
- I^2: 53%
- RR: 0.63 [0.39, 1.02]
- p^1: 0.06
- Studies (patients), n: 4 (604)
- I^2: 52%
- WMD: 0.02 [1.10, 1.07]
- p^2: 0.98

**COPD**
- Studies (patients), n: 3 (1813)
- I^2: 50%
- RR: 0.97 [0.77, 1.22]
- p^1: 0.79
- Studies (patients), n: 3 (1813)
- I^2: 61%
- WMD: 0.24 [0.94, 1.42]
- p^2: 0.69

**Previous AF**
- Included: 2 (1795)
- I^2: 0%
- RR: 0.97 [0.84, 1.11]
- p^1: 0.64
- Excluded: 7 (928)
- I^2: 60%
- WMD: 0.16 [0.94, 0.61]
- p^2: 0.68

**Baseline LVEF**
- <55%: 4 (546)
- I^2: 32%
- RR: 0.70 [0.46, 1.06]
- p^1: 0.09
- ≥55%: 4 (2038)
- I^2: 59%
- WMD: 0.37 [1.01, 0.27]
- p^2: 0.26

**Baseline LAD**
- <40mm: 3 (511)
- I^2: 68%
- RR: 0.58 [0.32, 1.06]
- p^1: 0.08
- ≥40mm: 3 (1711)
- I^2: 0%
- WMD: 0.01 [0.26, 0.25]
- p^2: 0.97

**Valvular surgery**
- Included: 4 (2121)
- I^2: 0%
- RR: 0.94 [0.84, 1.06]
- p^1: 0.34
- Excluded: 4 (2121)
- I^2: 74%
- WMD: 0.26 [0.54, 1.05]
- p^2: 0.53
Table 5. Cont.

| POAF incidence | LOH after surgery |
|----------------|-------------------|
|                | Studies (patients), n | i² | RR [95% CI] | p³ | p² | Studies (patients), n | i² | WMD [95% CI] | p³ | p² |
| Excluded       | 5 (566) | 69% | 0.66 [0.38, 1.15] | 0.14 | 0.22 | 4 (464) | 65% | −0.03 [-1.04, 0.97] | 0.95 | 0.66 |
| Off-pump surgery | 6 (2282) | 34% | 0.88 [0.73, 1.07] | 0.19 | 5 (2180) | 78% | 0.04 [-0.62, 0.69] | 0.92 |
| Excluded       | 3 (405) | 76% | 0.79 [0.45, 1.38] | 0.41 | 0.73 | 3 (405) | 56% | 0.21 [-1.36, 1.78] | 0.79 | 0.84 |
| Beta-blockers used | 4 (1963) | 56% | 0.79 [0.58, 1.07] | 0.13 | 4 (1963) | 50% | −0.34 [-0.92, 0.24] | 0.25 |
| ≥ 70% | 4 (622) | 57% | 0.94 [0.69, 1.29] | 0.71 | 0.43 | 4 (622) | 13% | 0.84 [0.25, 1.42] | 0.005 | 0.005 |
| ACEI/ARB used | 3 (1852) | 0% | 0.97 [0.84, 1.11] | 0.62 | 3 (1852) | 81% | 0.34 [-0.42, 1.09] | 0.38 |
| ≥ 55% | 4 (565) | 75% | 0.70 [0.42, 1.15] | 0.15 | 0.22 | 4 (565) | 66% | −0.18 [-1.42, 1.07] | 0.78 | 0.49 |
| Statins used | 4 (1877) | 70% | 0.65 [0.37, 1.12] | 0.12 | 4 (1877) | 42% | −0.27 [-0.76, 0.23] | 0.29 |
| ≥70% | 3 (540) | 49% | 0.96 [0.71, 1.29] | 0.76 | 0.22 | 3 (540) | 47% | 0.82 [-0.21, 1.86] | 0.12 | 0.06 |
| Amiodarone used | 1 (1516) | – | 0.97 [0.84, 1.13] | 0.74 | 1 (1516) | – | 0.00 [-0.26, 0.26] | 1.00 |
| Excluded       | 8 (1171) | 53% | 0.81 [0.63, 1.03] | 0.09 | 0.20 | 7 (1069) | 72% | 0.10 [-0.74, 0.93] | 0.82 | 0.83 |
| Fish oil regimen | 1 (102) | – | 0.58 [0.26, 1.20] | 0.14 | – | – | – | – |
| Intravenously supplied | 8 (2585) | 52% | 0.88 [0.72, 1.08] | 0.18 | 0.28 | 8 (2585) | 69% | 0.10 [-0.48, 0.67] | 0.75 | – |
| Orally supplied | 8 (2223) | 75% | 0.68 [0.34, 1.35] | 0.27 | 4 (2223) | 65% | −0.03 [-1.04, 0.97] | 0.95 |
| ≥ 1.8g/d | 5 (2223) | 0% | 0.93 [0.83, 1.05] | 0.24 | 0.37 | 4 (2223) | 74% | 0.26 [-0.54, 1.05] | 0.53 | 0.66 |
| EPA dose | 4 (464) | 75% | 0.68 [0.34, 1.35] | 0.27 | 4 (464) | 65% | −0.03 [-1.04, 0.97] | 0.95 |
| ≥ 1/g/d | 4 (2030) | 0% | 1.00 [0.89, 1.13] | 0.99 | 0.002 | 4 (2030) | 77% | 0.58 [-0.20, 1.37] | 0.15 | 0.01 |
| DHA dose | 5 (2224) | 2% | 0.97 [0.86, 1.09] | 0.59 | 5 (2224) | 73% | 0.44 [-0.31, 1.20] | 0.25 |
| ≥ 1.2 | 4 (463) | 0% | 0.50 [0.34, 0.74] | <0.001 | 3 (361) | 0% | −0.61 [-1.19, -0.03] | 0.04 | 0.03 |
| POAF incidence in controls | 4 (2223) | 75% | 0.68 [0.34, 1.35] | 0.27 | 4 (2223) | 65% | –0.03 [-1.04, 0.97] | 0.95 |
of fish oil supplementation on POAF, which may be an important source of heterogeneity among the included studies. Particularly, supplements with a relatively higher amount of DHA (≥1g/d) seemed to relate to a significant decreased risk of POAF and LOH after surgery, while did not for supplements with lower amount of DHA, suggesting that DHA may be the determinant for the potential preventative effect of fish oil for POAF. These findings are consistent with the results of recent cross-sectional [44] and cohort studies [45,46], which suggested that lower serum content of DHA but not EPA was independently associated with increased risk of AF in humans. Although the exact mechanisms underlying the possible different effects of DHA and EPA on POAF are unknown, there is some evidence from studies in animals and humans [47,48] which indicated that compared to EPA, DHA can favorably influence some physiological processes involved in AF pathogenesis in a more effective way, such as anti-inflammation and reduction of heart rate. Besides, previous studies demonstrated that although supplying with pure DHA can also raise serum and tissue levels of EPA, the reverse cannot be achieved [47]. Furthermore, DHA is more abundant than EPA in the myocardium, also reflecting that DHA may be more important for the normal heart function [11]. However, our findings that supplements with higher DHA (≥1g/d) was associated with reduced POAF incidence and LOH after surgery should be interpreted with caution because 3 of the five comparisons included in the subgroup were of open-label design, and the numbers of the patients included in the subgroup (n = 657) are only a small part of the patients included in the whole analysis (about 24.5%).

Previous studies suggested that pretreatment of medications such as ACEIs/ARBs [49], statins [50] and β-blockers [51] may reduce the incidence of POAF, and the incidence of POAF may also decrease if off-pump cardiac surgeries were applied [52]. However, results of meta-regression and subgroup analyses seemed not to support that the above factors may influence the effects of fish oil supplementation on POAF. Of note, because we do not have individual patient data of the included studies, these meta-regression and subgroup analyses were generally based on the proportions of the included patients in each study who were pretreated with these medications or performed with off-pump surgeries. Obviously, results of these subgroup analyses should be interpreted cautiously and future studies are needed to evaluate whether fish oil supplementation could reduce the incidence of POAF in those who were not pretreated with these medications or in those who received on-pump cardiac surgeries.

Results of our study also indicated that fish oil supplementation did not significantly influence the perioperative mortality, POAF incidence and LOH after cardiac surgery (Table 5).

### Table 5. Cont.

| Studies (patients), n | I^2 | RR [95% CI] | p1 | p2 | WMD [95% CI] | p1 | p2 |
|-----------------------|-----|-------------|----|----|---------------|----|----|
| <33% | 5 (2062) | 39% | 0.83 | [0.63, 1.09] | 0.17 | | 4 (1960) | 72% | 0.28 | [−0.38, 0.94] | 0.41 |
| ≥33% | 4 (625) | 68% | 0.87 | [0.62, 1.21] | 0.40 | 0.84 | 4 (625) | 67% | −0.13 | [−1.42, 1.16] | 0.84 | 0.58 |

### Jadad Scores

| ≥3 | 6 (874) | 51% | 0.72 | [0.52, 1.08] | 0.05 | 5 (727) | 77% | −0.01 | [−0.95, 0.93] | 0.98 |
| >3 | 3 (1813) | 50% | 0.97 | [0.77, 1.22] | 0.79 | 0.11 | 3 (1813) | 61% | 0.24 | [−0.94, 1.42] | 0.69 | 0.74 |

1 p values for subgroup effects.
2 p values for subgroup interaction.

POAF, post-operative atrial fibrillation; LOH, length of hospitalization; RR, relative risk; WMD, weighed mean difference; HTN, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; DHA, ducosahexaenoic acid; EPA, eicosapentaenoic acid.

![Figure 6. Funnel plots (with pseudo 95% CIs) of all the individual studies in the meta-analyses for the effects of fish oil supplementation on POAF incidence (A) and LOH after cardiac surgery (B). POAF, postoperative atrial fibrillation; LOH, length of hospitalization; RR, risk ratio; WMD, weighed mean difference, SE, standard error; CI, confidence interval. doi:10.1371/journal.pone.0072913.g006](https://doi.org/10.1371/journal.pone.0072913.g006)
incidence of major bleeding or the length of ICU stay after surgery. These results, together with the facts that none of the included study reported serious adverse events which were deemed to be caused by fish oil supplementation, suggested that fish oil is safe and well tolerated by these patients.

Several potential limitations should be concerned regarding the present meta-analyses. Firstly, the included studies were different in study scale and design, patient characteristics, concurrent therapy, surgical performance and regimens of fish oil supplementation, which may contribute to the heterogeneity among the studies. Besides, these studies also lack homogeneity in both method of postoperative monitoring and in the definition of POAF, which may make the interpretation of the results difficult. Moreover, the baseline status of serum contents of n-3 PUFAs before the trials was not collected in some studies, which may influence the effect of fish oil supplementation on POAF. Finally, as described previously, some relatively low-quality studies were included, and the numbers of studies and patients included for some subgroup analysis were small, so interpretation of the subgroup results should be with caution.

In conclusion, results of our meta-analysis did not support the preventative effects of perioperative fish oil supplementation for the incidence of POAF, although fish oil can be safe and well tolerated by these patients and did not significantly affect the perioperative mortality, incidence of major bleeding, and hospital and ICU stays.

In addition, relative amount of DHA and EPA seemed to be an important modifier of the effect of fish oil for POAF. Supplements with DHA >1 g/d may be associated with a significant reduced risk of POAF, while did not for supplements with lower dose of DHA.

Results of our study indicated that DHA and EPA may be different for prevention of POAF. Although these findings need to be confirmed in future clinical trials and experimental studies, our study highlighted the fact that the relative amounts of DHA and EPA in fish oil is important for at least some of its cardioprotective effects, such as prevention of POAF.

Supporting Information

Checklist S1 PRISMA Checklist.

(DOC)

Author Contributions

Conceived and designed the experiments: WX WW ZL SM. Performed the experiments: WX WW ZL XZ HY BL TZ. Contributed reagents/materials/analysis tools: WX WW SM. Wrote the paper: WX WW ZL SM.

References

1. Ershahidi N, Pharoat P, O’Hara G, Mathieu P (2006) Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51: 793–801.
2. Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, et al. (1996) Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 276: 300–306.
3. Zaman AG, Archbold RA, Heili G, Paul EA, Curzen NP, et al. (2000) Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification. Circulation 101: 1403–1408.
4. Mitchell LB (2011) Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 27: 91–97.
5. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, et al. (1997) Predictors of atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 226: 501–511; discussion 511–503.
6. Aranfki SF, Shaw DP, Adams DH, Rizzo RJ, Cooper GS, et al. (1996) Predictors of atrial fibrillation after coronary artery surgery: Current trends and impact on hospital resource utilization. Circulation 94: 390–397.
7. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferreira E, et al. (2008) Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 118: 1612–1618.
8. Baudry D, Creswell LL, Hogge CW Jr, Epstein AE, Prystowsky EN, et al. (2005) Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 128: 398–478.
9. Rizos EC, Ntazni EE, Bika E, Kostapanos MS, Elisaf MS (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308: 1024–1033.
10. De Caterina R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364: 2439–2450.
11. Lavie CJ, Milani RV, Mehta MR, Ventura HO (2009) Omega-3 polyunsaturated fatty acids and cardiovascular disease. J Am Coll Cardiol 54: 585–594.
12. Mozaffarian D, Wu JJH (2013) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 60: 2047–2067.
13. Saravanan P, Davidson NC, Schmidt EB, Calder PC (2010) Cardiovascular effects of marine omega-3 fatty acids. Lancet 376: 540–550.
14. Kitamura K, Shibata R, Tsuji Y, Shimano M, Inden Y, et al. (2011) Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. Am J Physiol Heart Circ Physiol 300: H1814–H1821.
15. Lau DH, Psaltis PJ, Carbone A, Kelley DJ, Mackenzie L, et al. (2011) Atrial protective effects of n-3 polyunsaturated fatty acids: a long-term study in oxine chronic heart failure. Heart Rhythm 8: 575–582.
16. Kumar S, Sutherland F, Teh AW, Heck PM, Lee G, et al. (2011) Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human pulmonary vein and left atrial electrophysiology in paroxysmal atrial fibrillation. Am J Cardiol 108: 531–535.
17. Kumar S, Sutherland F, Rossouw R, Teh AW, Lee G, et al. (2011) Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology. Heart Rhythm 8: 562–568.
18. Calo L, Bianconi L, Colivicchi F, Lamorte F, Girolamo ML, et al. (2005) N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45: 1723–1728.
19. Heidt MC, Vician M, Stracke SK, Stadt Bauer T, Grebe MT, et al. (2009) Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg 57: 276–280.
20. Saravanan P, Bridgewater B, West AL, O’Neill SC, Calder PC, et al. (2010) Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 3: 46–53.
21. Headshon E, Al-Nasser DO, Skaladotors GV, Torslason R, Edwardsson V, et al. (2010) Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 12: 336–363.
22. Farquharson AL, Metcalf RG, Sanders P, Stuikin R, Edwards JR, et al. (2011) Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol 108: 851–856.
23. Sorice M, Tritto FP, Sordelli C, Gregorio R, Piazza L (2011) N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing “on-pump” coronary artery bypass graft surgery. Monaldi Arch Chest Dis 76: 93–98.
24. Sandeasa CM, Chung MK, Van Wagoner DR, Barringer TA, Allen K, et al. (2012) A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids For Inhibition of Supraventricular Arrhythmias After Cardiac Surgery: The FISH Trial. J Am Heart Assoc 1: e000047.
25. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrari A, et al. (2012) Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids For Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 306: 2001–2011.
26. Mohr D, Liberati A, Testad B, Almahn D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
27. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration www.cochrane-handbook.org.
28. Mohr D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609–613.
29. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2005) Measuring inconsistency in meta-analyses. BMJ 332: 557–560.
31. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
32. Mozaffarian D, Putsay BM, Rimn EM, Lemaire RN, Burke GL, et al. (2004) Fish intake and risk of incident atrial fibrillation. Circulation 110: 368–373.
33. Frost L, Vestergaard P (2005) n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 81: 50–54.
34. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Wittmer JA (2006) Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 151: 857–862.
35. Berry JD, Primeau RF, van Horn L, Passman R, Larson J, et al. (2010) Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 105: 844–848.
36. Sheri J, Johnson VM, Sullivan LM, Jacques PF, Magnani JW, et al. (2011) Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am J Clin Nutr 93: 261–266.
37. Yang Y, Lu N, Chen D, Meng L, Zheng Y, et al. (2012) Effects of n-3 PUFA supplementation on plasma soluble adhesion molecules: a meta-analysis of randomized controlled trials. Am J Clin Nutr 95: 972–980.
38. Xin W, Wei W, Li X (2012) Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 12: 77.
39. Xin W, Wei W, Li X (2012) Effect of fish oil supplementation on fasting vascular endothelial function in humans: a meta-analysis of randomized controlled trials. PLoS One 7: e46029.
40. Xin W, Wei W, Li X (2012) Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomized controlled trials. Heart 98: 1620–1625.
41. Christensen JH, Svensson M, Strandhave C, Madsen T, Schmidt EB (2010) n-3 fatty acids and cardiac autonomic function in humans. Cell Mol Biol (Noisy-le-Grand) 56: 131–139.
42. Xin W, Wei W, Li XY (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97: 926–935.
43. He Z, Yang L, Tian J, Yang K, Wu J, et al. (2013) Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can J Cardiol 29: 196–203.
44. Kirkegaard E, Svensson M, Strandhave C, Schmidt EB, Jorgensen KA, et al. (2012) Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients. Br J Nutr 107: 903–909.
45. Virtanen JK, Mursu J, Vuotilainen S, Tuomainen TP (2009) Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 120: 2315–2321.
46. Wu JH, Lemaître RN, King IB, Song X, Sacks FM, et al. (2012) Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation 125: 1094–1093.
47. Mori TA, Woodman RJ (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9: 95–104.
48. Mozaffarian D, Wu JH (2012) n-3 fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 142: 614S–625S.
49. Ozaydin M, Dede O, Varol E, Kapa S, Turkler Y, et al. (2008) Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation. Int J Cardiol 127: 362–367.
50. Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, et al. (2009) Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 138: 670–686 e671.
51. Khan HF, Wendel CS, Mwalule MR (2013) Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol 18: 50–68.
52. Athanasiou T, Aziz O, Mangoush O, Weerasinghe A, Al-Ruzzeh S, et al. (2004) Do off-pump techniques reduce the incidence of postoperative atrial fibrillation in elderly patients undergoing coronary artery bypass grafting? Ann Thorac Surg 77: 1567–1574.